HPV-Associated Anal Cancer in the HIV/AIDS Patient
- 7 December 2018
- book chapter
- Published by Springer Nature
- Vol. 177, 183-209
Abstract
The prevalence of anal human papillomavirus (HPV) infection and anal high-grade squamous intraepithelial lesion (HSIL) remain high among HIV-infected individuals on effective antiretroviral therapy (ART). The incidence of HPV-related anal cancers has continued to increase since the introduction of ART. Therefore, ART may confer only limited benefit with respect to reducing the risk of anal HSIL and cancer. Efforts are in progress to define the efficacy of secondary prevention programs for prevention of anal cancer. In the modern ART era, anal cancer recurrence and survival outcomes are similar in HIV-infected and HIV-uninfected patients, but HIV-infected patients may experience more toxicities. This article reviews the current literature on HPV-associated anal cancer in the HIV-infected population, including epidemiology, screening, clinical characteristics, and treatment outcomes.Keywords
This publication has 141 references indexed in Scilit:
- Evidence Regarding Human Papillomavirus Testing in Secondary Prevention of Cervical CancerVaccine, 2012
- HPV Vaccine against Anal HPV Infection and Anal Intraepithelial NeoplasiaNew England Journal of Medicine, 2011
- Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine TrialThe Lancet Oncology, 2011
- Use of antineoplastic agents in patients with cancer who have HIV/AIDSThe Lancet Oncology, 2011
- Use of Surveillance, Epidemiology, and End Results-Medicare Data to Conduct Case-Control Studies of Cancer Among the US ElderlyAmerican Journal of Epidemiology, 2011
- Safety and Immunogenicity of the Quadrivalent Human Papillomavirus Vaccine in HIV‐1–Infected MenThe Journal of Infectious Diseases, 2010
- Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)British Journal of Cancer, 2010
- Influence of Adherent and Effective Antiretroviral Therapy Use on Human Papillomavirus Infection and Squamous Intraepithelial Lesions in Human Immunodeficiency Virus–Positive WomenThe Journal of Infectious Diseases, 2010
- Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survivalThe Lancet Oncology, 2010
- Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort studyThe Lancet Oncology, 2009